Personalized medicine-based strategy for prostate cancer
Author:
Publisher
International Society of Personalized Medicine
Subject
General Medicine
Reference9 articles.
1. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer;Kubo;Hum Gene Ther,2003
2. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: initial experience at Kobe University;Hinata;Int J Urol,2006
3. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer;Shirakawa;Hum Gene Ther,2007
4. A pilot study of quality of life of patients with hormone refractory prostate cancer after gene therapy;Terao;Anticancer Res,2009
5. Improved gene transfer into renal carcinoma cells using adenovirus vector containing RGD motif;Terao;Anticancer Res,2009
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of pharmacogenomics for prediction of personalized medicines;Biochemistry of Drug Metabolizing Enzymes;2022
2. Galaxy and MEAN Stack to Create a User-Friendly Workflow for the Rational Optimization of Cancer Chemotherapy;Frontiers in Genetics;2021-02-18
3. The Impact of Pharmacogenomics in Personalized Medicine;Current Applications of Pharmaceutical Biotechnology;2019
4. Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine;Future Oncology;2016-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3